Yugandhar Munnangi, MD
Psychiatry · Yonkers, NYNPI 1316913932
Payments from drug & device makers
Across 926 payments — averaging $279.83 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Teva Pharmaceuticals USA, Inc.$86K
- Johnson & Johnson$84K
- Otsuka America Pharmaceutical, Inc.$65K
- AbbVie$13K
- Neurocrine Biosciences, Inc.$3K
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$2K
- plus $4K from 15 others
What the payments were for
- Consulting fees$2,8601%
- Speaking & faculty fees$216,93384%
- Travel & lodging$12,4855%
- Food & beverage$26,62310%
- Education$2220%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Teva Pharmaceuticals USA, Inc. | 196 | $86,417 |
| Johnson & Johnson | 194 | $84,267 |
| Otsuka America Pharmaceutical, Inc. | 156 | $65,309 |
| AbbVie(2 entities) | 165 | $12,947 |
| Neurocrine Biosciences, Inc. | 37 | $3,377 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 52 | $2,363 |
| Alkermes, Inc. | 41 | $1,489 |
| Axsome Therapeutics, Inc. | 8 | $582 |
| Vanda Pharmaceuticals Inc. | 23 | $543 |
| E.r. Squibb & Sons, L.L.C. | 16 | $402 |
| Sunovion Pharmaceuticals Inc. | 4 | $345 |
| Avanir Pharmaceuticals, Inc. | 6 | $209 |
| Eisai Inc. | 6 | $167 |
| Indivior Inc. | 8 | $155 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $125 |
| Braeburn Inc. | 1 | $125 |
| Idorsia Pharmaceuticals US Inc | 2 | $119 |
| Lundbeck LLC | 4 | $90 |
| Almatica Pharma LLC | 3 | $44 |
| Luye Pharma (USA) Ltd. | 2 | $34 |
| Alfasigma USA, Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- INVEGA SUSTENNA$81,112
- INVEGA TRINZA$80,132
- ABILIFY MAINTENA$62,422
- AUSTEDO$45,332
- Austedo XR$35,030
- ABILIFY ASIMTUFII$27,154
- VRAYLAR$10,443
- UZEDY$3,457
- INGREZZA$2,887
- CAPLYTA$1,677
- LYBALVI$1,360
- REXULTI$1,125
- SPRAVATO$780
- ARISTADA$488
- Auvelity$468
- COBENFY$345
- LATUDA$240
- NURTEC ODT$125
- BRIXADI$125
- ARISTADA INITIO$122
How this compares
$259,123 in reported general payments places this provider in the 95th percentile of 3,713 psychiatry providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| IngrezzaValbenazine Tosylate | 24 | $193,440 |
| VraylarCariprazine Hcl | 40 | $55,110 |
| RexultiBrexpiprazole | 39 | $54,484 |
| Invega SustennaPaliperidone Palmitate | 17 | $47,928 |
| Lurasidone Hcl | 17 | $8,245 |
| Aripiprazole | 123 | $6,316 |
| VyvanseLisdexamfetamine Dimesylate | 17 | $5,183 |
| Quetiapine Fumarate | 241 | $4,588 |
| Paliperidone ErPaliperidone | 25 | $3,772 |
| Divalproex Sodium ErDivalproex Sodium | 58 | $2,618 |
| Bupropion XlBupropion Hcl | 131 | $2,433 |
| Clonazepam | 273 | $2,351 |
| Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine | 84 | $2,283 |
| Fluphenazine Hcl | 23 | $2,131 |
| Divalproex Sodium | 52 | $1,736 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Neurocrine Biosciences, Inc.Ingrezza | $3,377 | $193,44024 claims |
| AbbVieVraylar | $12,947 | $55,11040 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $65,309 | $54,48439 claims |
| Johnson & JohnsonInvega Sustenna | $84,267 | $47,92817 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 3,713 psychiatry providers in New York.
Other psychiatry in Yonkers
- Yadagiri ChepuruYonkers$963K
- Elyssa BarronWhite Plains$12.8M
- Mark DibuonoStaten Island$11.9M
- Ronald BrennerHempstead$11.5M
- Anton PorsteinssonRochester$7.6M
- Michael LiebowitzNew York$7.1M
- Leslie CitromePomona$5.7M
- John KaneGlen Oaks$4M
- Inna Yuryev-GolgerBrooklyn$3M
- Subhdeep VirkBuffalo$3M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.